Last 12 months
Inside the activity.
0 purchase rows · 145 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 9 |
| Dec 2025 | 0 | 8 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 41 |
| Apr 2026 | 0 | 26 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 11 |
| Aug 2026 | 0 | 11 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 18 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 15, 2020 Filed May 18, 2020 21:00 UTC |
SANG CHARLESSVP, Clinical Diagnostics
|
Exercise / conversionCommon Stock | 20,000 | $6.55 | $131,000.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · nonDerivative · entry 2 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 18, 2020 21:00 UTC |
SANG CHARLESSVP, Clinical Diagnostics
|
Exercise / conversionCommon Stock | 20,000 | $6.32 | $126,400.00 |
DisclosureSEC source: 0001209191-20-030299 · doc4.xml · nonDerivative · entry 1 SANG CHARLES · CIK 0001780656 · SVP, Clinical Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 35,400 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · derivative · entry 16 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,600 Underlying: Common Stock · 35,400 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F11 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 7,158 | $38.11 | $272,791.38 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.98 to 38.26, inclusive. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 22,342 | $37.53 | $838,495.26 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,837 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.98 to 37.97, inclusive. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 5,400 | $36.34 | $196,236.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,179 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.80 to 36.72, inclusive. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 400 | $35.13 | $14,052.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,579 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.71 to 35.53, inclusive. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 100 | $33.56 | $3,356.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,979 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 35,400 | $6.32 | $223,728.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-20-030301 · doc4.xml · derivative · entry 5 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,000 Underlying: Common Stock · 2,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 398 | $36.10 | $14,367.80 |
DisclosureSEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 4 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.89 to 36.33, inclusive. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 400 | $35.23 | $14,092.00 |
DisclosureSEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.82 to 35.68, inclusive. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 1,202 | $34.14 | $41,036.28 |
DisclosureSEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 798 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.75 to $34.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 15, 2020 Filed May 19, 2020 01:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionCommon Stock | 2,000 | $0.45 | $900.00 |
DisclosureSEC source: 0001209191-20-030301 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| May 14, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 31,200 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · derivative · entry 15 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 31,200 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F11 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 14, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 28,000 | $35.44 | $992,320.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.92 to 35.91, inclusive. Read SEC document |
| May 14, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 3,200 | $34.26 | $109,632.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.91 to 34.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 14, 2020 Filed May 19, 2020 01:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionCommon Stock | 31,200 | $6.32 | $197,184.00 |
DisclosureSEC source: 0001209191-20-030300 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,879 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| May 12, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · derivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 30,000 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 12, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 5,140 | $39.13 | $201,128.20 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.00 to 39.35, inclusive. Read SEC document |
| May 12, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 24,860 | $38.20 | $949,652.00 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,140 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.00 to 38.96, inclusive. Read SEC document |
| May 12, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 30,000 | $0.84 | $25,200.00 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| May 11, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · derivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 80,000 shares Expires 2024-03-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 11, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
SaleCommon Stock | 80,000 | $38.00 | $3,040,000.00 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.00 to 38.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 11, 2020 Filed May 13, 2020 01:00 UTC |
RUBINSTEIN JULIEPresident
|
Exercise / conversionCommon Stock | 80,000 | $0.84 | $67,200.00 |
DisclosureSEC source: 0001209191-20-028689 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2019. Read SEC document |
| May 08, 2020 Filed May 13, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionStock Option (Right To Buy) · Derivative | 20,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-028688 · doc4.xml · derivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,000 Underlying: Common Stock · 20,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 08, 2020 Filed May 13, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
SaleCommon Stock | 20,000 | $35.92 | $718,400.00 |
DisclosureSEC source: 0001209191-20-028688 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.51 to 36.26, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 08, 2020 Filed May 13, 2020 01:00 UTC |
Cohen Chad MChief Financial Officer
|
Exercise / conversionCommon Stock | 20,000 | $6.32 | $126,400.00 |
DisclosureSEC source: 0001209191-20-028688 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-028110 · doc4.xml · derivative · entry 6 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,560 Underlying: Common Stock · 45,000 shares Expires 2021-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The options are fully vested and exercisable. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 8,814 | $36.13 | $318,449.82 |
DisclosureSEC source: 0001209191-20-028110 · doc4.xml · nonDerivative · entry 3 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,878,180 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.00 to 36.45, inclusive. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
SaleCommon Stock | 36,186 | $35.47 | $1,283,517.42 |
DisclosureSEC source: 0001209191-20-028110 · doc4.xml · nonDerivative · entry 2 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886,994 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.00 to 35.99, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
ROBINS CHAD MDirector · CEO and Chairman
|
Exercise / conversionCommon Stock | 45,000 | $0.33 | $14,850.00 |
DisclosureSEC source: 0001209191-20-028110 · doc4.xml · nonDerivative · entry 1 ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,923,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
DOBMEIER ERICDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-028108 · doc4.xml · derivative · entry 3 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 5,000 shares Expires 2026-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. F2 · derivative.exercise_date: The options vested with respect to 1/4 of the reporting person's shares on September 28, 2017, with an additional 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
DOBMEIER ERICDirector
|
SaleCommon Stock | 5,000 | $35.00 | $175,000.00 |
DisclosureSEC source: 0001209191-20-028108 · doc4.xml · nonDerivative · entry 2 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| May 07, 2020 Filed May 9, 2020 00:00 UTC |
DOBMEIER ERICDirector
|
Exercise / conversionCommon Stock | 5,000 | $6.32 | $31,600.00 |
DisclosureSEC source: 0001209191-20-028108 · doc4.xml · nonDerivative · entry 1 DOBMEIER ERIC · CIK 0001202785 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 25, 2019. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-028109 · doc4.xml · derivative · entry 4 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 50,000 shares Expires 2029-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F4 · derivative.exercise_date: The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 550 | $34.55 | $19,002.50 |
DisclosureSEC source: 0001209191-20-028109 · doc4.xml · nonDerivative · entry 3 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.44 to 34.61, inclusive. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:00 UTC |
BALDO LANCEChief Medical Officer
|
SaleCommon Stock | 49,450 | $33.85 | $1,673,882.50 |
DisclosureSEC source: 0001209191-20-028109 · doc4.xml · nonDerivative · entry 2 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.31 to 34.24, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 06, 2020 Filed May 9, 2020 00:00 UTC |
BALDO LANCEChief Medical Officer
|
Exercise / conversionCommon Stock | 50,000 | $7.80 | $390,000.00 |
DisclosureSEC source: 0001209191-20-028109 · doc4.xml · nonDerivative · entry 1 BALDO LANCE · CIK 0001780773 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 11,270 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-20-026231 · doc4.xml · derivative · entry 5 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,730 Underlying: Common Stock · 11,270 shares Expires 2028-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,310 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-026231 · doc4.xml · derivative · entry 4 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,690 Underlying: Common Stock · 8,310 shares Expires 2029-04-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
SaleCommon Stock | 19,580 | $30.22 | $591,707.60 |
DisclosureSEC source: 0001209191-20-026231 · doc4.xml · nonDerivative · entry 3 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.00 to 30.51, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 11,270 | $6.55 | $73,818.50 |
DisclosureSEC source: 0001209191-20-026231 · doc4.xml · nonDerivative · entry 2 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 27, 2020 Filed Apr 29, 2020 20:00 UTC |
Taylor Stacy LSVP and General Counsel
|
Exercise / conversionCommon Stock | 8,310 | $7.80 | $64,818.00 |
DisclosureSEC source: 0001209191-20-026231 · doc4.xml · nonDerivative · entry 1 Taylor Stacy L · CIK 0001799081 · SVP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 00:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-20-025881 · doc4.xml · derivative · entry 3 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 00:00 UTC |
HERSHBERG ROBERTDirector
|
SaleCommon Stock | 25,000 | $29.77 | $744,250.00 |
DisclosureSEC source: 0001209191-20-025881 · doc4.xml · nonDerivative · entry 2 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.41 to 30.35, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 23, 2020 Filed Apr 28, 2020 00:00 UTC |
HERSHBERG ROBERTDirector
|
Exercise / conversionCommon Stock | 25,000 | $0.45 | $11,250.00 |
DisclosureSEC source: 0001209191-20-025881 · doc4.xml · nonDerivative · entry 1 HERSHBERG ROBERT · CIK 0001274139 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2020. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 25,600 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · derivative · entry 15 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,200 Underlying: Common Stock · 25,600 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 25,500 | $30.28 | $772,140.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 10 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.76 to 30.72, inclusive. Read SEC document |
| April 22, 2020 Filed Apr 23, 2020 00:00 UTC |
ROBINS HARLAN SChief Scientific Officer
|
SaleCommon Stock | 100 | $29.63 | $2,963.00 |
DisclosureSEC source: 0001209191-20-025389 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,179 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.63 to 29.64. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.